Global Market for DNA Vaccines to Reach $2.7 Billion in 2019; Clinical Vaccines Segment Surging at 81.2% CAGR

News provided by

Aug 05, 2014, 09:00 ET

WELLESLEY, Massachusetts, August 5, 2014 /PRNewswire/ --

BCC Research (http://www.bccresearch.com) reveals in its new report, DNA VACCINES: TECHNOLOGIESAND GLOBAL MARKETS, the global market for DNA vaccines is expected to grow to $2.7 billion by 2019, with a five-year compound annual growth rate (CAGR) of 54.8%. The clinical vaccines category, the largest and fastest-growing segment of this market, is surging at 81.2% CAGR.

Logo (PRNewsFoto/BCC Research)

(Logo: http://photos.prnewswire.com/prnh/20140805/700528 )

Once a stable though unexciting sector of the pharmaceutical industry, vaccines are fast becoming an attractive growth opportunity. DNA vaccines, which target a wide range of traditional pharmaceutical markets such as cancers, allergies, and infectious diseases, are an emerging vaccine platform within this changing paradigm.

With biotechnologies and nanotechnologies driving tremendous growth in DNA vaccine development, the clinical vaccines segment, which was valued at just $78 million in 2013, is expected to grow to $2.4 billion in 2019. Key to this growth is emerging delivery technologies that are demonstrating the higher efficacy in humans required for commercialization of DNA vaccines.

Consequently, research tools and animal health play a vital role in the development of the large, human vaccine applications. This segment is expected to reach $308 million by 2019, registering a significant CAGR of 11.1%.

"The diversity and number of clinical trials points toward initial introduction of products with significant market potential late in the forecast period," says BCC Research biotechnology analyst Jon Evans. "These products, together with newly introduced therapeutic vaccines already on the market, will transform the future of the vaccine industry."

Human clinical DNA vaccines represent the primary future market opportunity for this industry. The momentum for commercialization of a human DNA vaccine is growing due to the inherent advantages of DNA vaccines over other vaccine formats and an emerging consensus within the vaccine industry that DNA vaccines are safe and efficacious in humans.

DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS provides an overview of the global market for DNA vaccines and related research tools. It includes analyses of global market trends, with data from 2013, estimates for 2014, projections of CAGRs through 2019, and profiles of companies important in the industry.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at [email protected].

About BCC Research

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years, we have helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world as well as universities, business schools, start-ups, consulting firms and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or E-mail [email protected].

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49-2 Walnut Park, Wellesley, MA 02481, Telephone: (+1) 781-489-7301; E-mail: [email protected] as the source and publisher. Thank you.

Contact: Steven Cumming

Tel: +1-978-870-3345
Fax: +1-781-489-7308
Email: [email protected]

SOURCE BCC Research LLC